The Biden administration announced Monday it has initiated an investigation into pharmaceutical imports and their potential impact on national security, laying groundwork for possible industry-wide tariffs. The Department of Commerce’s probe, revealed through an online federal notice, encompasses both branded and generic
medications, along with their active pharmaceutical ingredients.
Commerce Secretary Howard Lutnick launched the investigation on April 1 under Section 232 authority – the same legal mechanism President Donald Trump recently employed to expand duties on steel and aluminum products. While the notices were posted April 14, they won’t be officially published in the Federal Register until Wednesday.
The pharmaceutical investigation, coupled with a parallel probe into semiconductors, aligns with previous signals from both Trump and Lutnick about their intentions to tax pharmaceutical imports, which have historically been exempt from trade levies. The pharmaceutical industry currently sources significant raw materials and active ingredients from Asian markets, particularly China and India, while maintaining substantial manufacturing operations in European countries including Switzerland, Ireland and the Netherlands.
“We need our medicines, and we need semiconductors and our electronics to be built in America,” Lutnick stated during an ABC News interview Sunday, explaining that tariffs would be implemented to encourage domestic production.
Several major pharmaceutical companies have already begun responding to the anticipated tariffs. Eli Lilly, Johnson & Johnson, and Novartis have announced multi-billion dollar investments in new U.S.-based manufacturing facilities. However, these plants will require years to construct and won’t immediately address the industry’s deep-rooted supply chain dependencies on Asian markets.
Financial analysts predict the tariffs could significantly impact drugmakers’ bottom lines, potentially forcing reductions in other areas such as research and development – a concern echoed by Eli Lilly CEO David Ricks in a recent BBC interview. Generic drug manufacturers, who operate with narrower profit margins than branded pharmaceutical companies, could face particularly severe challenges.
The Commerce Department is seeking public input within a three-week window on several key aspects, including domestic production capacity, import source concentration, feasibility of increased U.S.
manufacturing, and the potential impact of new trade measures on domestic output.
While Section 232 investigations typically conclude with a report to the president within 270 days, the administration may act more swiftly. Lutnick’s Sunday comments suggested pharmaceutical tariffs could be implemented within one to two months. According to Leerink Partners analyst David Risinger, the White House could alternatively impose tariffs using the same emergency legal authority it employed for recent global 10% tariffs.
The investigation’s scope demonstrates the administration’s broad approach to reshaping pharmaceutical supply chains, targeting not just finished products but also the fundamental components of drug manufacturing. This comprehensive examination reflects growing concerns about pharmaceutical supply chain security and the United States’ reliance on foreign manufacturers for critical medical supplies.
Major pharmaceutical companies face potential disruption to their established global supply networks, while smaller manufacturers and generic drug producers must navigate the prospect of increased costs in an already competitive market. The investigation marks a
significant shift in U.S. trade policy regarding pharmaceutical products, potentially reshaping the industry’s global manufacturing landscape in the years ahead.
Be First to Comment